Skip to main content
MNKD
NASDAQ Life Sciences

MannKind Secures $50M Private Placement as FDA Clears Furoscix ReadyFlow

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$4.11
Mkt Cap
$1.276B
52W Low
$2.23
52W High
$6.51
52W Position info
84% above low
Off High info
37% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

MNKD sits 84% above its 52-week low of $2.23.

Summary

MannKind raised $50 million in a private placement to cover a $45 million CVR payment triggered by FDA approval of Furoscix ReadyFlow, a new edema treatment. The deal includes pre-funded warrants and was priced at a 5% discount to market.


Key Events · Financing and Capital Events · MNKD

  • $50M Private Placement Priced at $3.89

    MannKind sold 10.4 million shares at $3.89 each and pre-funded warrants for 2.4 million shares at $3.88 per warrant share, raising $50 million in gross proceeds. The price represents a 5% discount to the current $4.11 stock price.

  • Proceeds Earmarked for $45M CVR Payment

    The net proceeds will fund a $45 million contingent value rights obligation triggered by the FDA approval of Furoscix ReadyFlow, with the remainder for general corporate purposes.

  • FDA Approves Furoscix ReadyFlow

    The FDA approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema in adults with heart failure or chronic kidney disease, expanding MannKind's cardiometabolic portfolio.

  • Pre-Funded Warrants Add Potential Dilution

    Investors received pre-funded warrants to purchase 2.4 million shares at $0.01 per share, exercisable at any time with no expiration, adding potential dilution of approximately 0.7% of outstanding shares.


Analysis · MNKD · Life Sciences

A $50 million private placement priced at $3.89 per share—a 5% discount to the current $4.11 market price—will primarily fund a $45 million contingent value rights payment triggered by the FDA's approval of Furoscix ReadyFlow, which was also announced in this filing. The deal includes pre-funded warrants for 2.4 million shares, adding potential dilution, and was led by Frazier Life Sciences, a longstanding biotech investor whose participation signals institutional confidence despite the discount. While the concurrent FDA approval expands MannKind's cardiometabolic franchise, the immediate capital raise underscores cash constraints following a $16.6 million Q1 loss.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNKD was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNKD - Latest Insights

MNKD
Nov 05, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.79
Real-time Price: $4.13 info
Change: +$0.340 (+9%) info
Market Cap: $1.328B info
MNKD
Nov 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $4.13 info
Change: +$0.370 (+10%) info
Market Cap: $1.328B info
MNKD
Sep 09, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $4.13 info
Change: -$0.150 (-4%) info
Market Cap: $1.328B info
MNKD
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.12
Real-time Price: $4.13 info
Change: +$0.0100 (+0.24%) info
Market Cap: $1.328B info
MNKD
Jul 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $4.13 info
Change: +$0.100 (+2%) info
Market Cap: $1.328B info